Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Gamifant Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C15970-A

    Gamifant (emapalumab-lzsg) Coverage Policy

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C15970-A alerts

    Get alerted when Policy C15970-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Molina Healthcare coverage and prior authorization for Gamifant (emapalumab-lzsg) used to treat primary or secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). Coverage is subject to member benefit eligibility, clinical criteria, required documentation, prescriber qualifications, and authorization duration limits.

    Policy Summary
    PayerMolina Healthcare
    PolicyGamifant (emapalumab-lzsg) Coverage Policy
    Policy CodePolicy C15970-A
    Change TypeNon-material revision
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionBefore initiating Gamifant, document testing for latent tuberculosis infection and evaluate tuberculosis risk factors.
    SourceLink
    POLICY UPDATE CHANGES

    The revision history identifies notable revisions to the Diagnosis and Quantity sections in Q3 2026.

    2Covered clinical indications
    6 monthsInitial authorization duration
    12 monthsMaximum primary HLH continuation
    10 mg/kgMaximum dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4 weeksLive vaccine restriction after last dose
    NoneAge restriction

    Covered Indications and General Coverage Rules

    Initial therapy - primary HLH

    Covered for primary HLH when ALL of the following are met.

    Primary HLH initial therapy

    • Diagnostic confirmation

      • Genetic confirmation: Genetic testing shows a mutation known to cause HLH, such as PRF1, UNC13D, or STX11.
      • Clinical and laboratory findings: The member has five of the listed HLH findings.5 findings

        Findings include fever >38.5 C for >7 days; splenomegaly; cytopenias affecting 2 of 3 lineages; hypertriglyceridemia and/or hypofibrinogenemia; hemophagocytosis without malignancy; low or absent NK-cell activity; ferritin ≥500 mcg/L; or soluble CD25 >2400 U/mL.

    • Primary cause excluded: The prescriber attests that malignancy, viral infection, and rheumatic disorders have been ruled out as potential primary causes of HLH.
    • Active disease: The prescriber attests to currently active disease within the last 3 months.Within 3 months
    • Refractory, recurrent, progressive, or intolerant disease: The member has not responded to or maintained a satisfactory response to conventional HLH therapy, or has serious side effects from conventional HLH treatment.

      Examples include dexamethasone, etoposide, cyclosporine A, and anti-thymocyte globulin.

    • Transplant eligibility: The member is eligible for stem cell transplant and has not received hematopoietic stem cell transplant (HSCT).No prior HSCT
    • Pre-HSCT use: Gamifant is used before HSCT for induction or maintenance and will be discontinued when conditioning begins.Before HSCT
    • Baseline markers: Baseline disease-specific markers are documented, including applicable clinical findings, complete blood count, fibrinogen and/or D-dimer, ferritin, soluble CD25, or other cytokine markers.

      Markers may include fever, splenomegaly, and central nervous system symptoms.

    • Concomitant dexamethasone: The treatment plan administers Gamifant concomitantly with dexamethasone.

      Claims may be reviewed for concomitant dexamethasone use.

    • Infection status: The prescriber attests that the member does not have an active or latent untreated infection, including clinically important localized infection, according to the FDA label.

      Examples include hepatitis B and tuberculosis.

    Initial therapy - secondary HLH/MAS

    Covered for secondary HLH/MAS when ALL of the following are met.

    Secondary HLH/MAS initial therapy

    • Underlying Still's disease: The member has confirmed or suspected Still's disease, including systemic juvenile idiopathic arthritis.
    • HLH/MAS diagnosis: The member has a documented diagnosis of HLH/MAS.
    • Diagnostic laboratory findings: Ferritin is >684 ng/mL and two qualifying laboratory findings are documented.Ferritin >684 ng/mL plus 2 findings

      Qualifying findings are platelets ≤181×10^9/L, AST >48 U/L, triglycerides >156 mg/dL, or fibrinogen ≤360 mg/dL.

    Continuation therapy - primary HLH

    Continuation for primary HLH requires ALL of the following.

    Primary HLH continuation therapy

    • Ongoing treatment need and no HSCT: The member has not received HSCT and continues to require therapy for HLH.
    • Clinical improvement: Disease-specific markers have improved, including applicable clinical, hematologic, ferritin, fibrinogen/D-dimer, lymphocyte, or cytokine markers.Improvement from baseline

      Additional markers that were especially high at diagnosis may also be used, such as NK-cell function or viral titers.

    • Tolerability: There is no evidence of intolerable adverse effects or drug toxicity, including serious infections or severe infusion reactions.

    Continuation therapy - secondary HLH/MAS

    Continuation for secondary HLH/MAS requires ALL of the following.

    Secondary HLH/MAS continuation therapy

    • Clinical and laboratory improvement: Laboratory values and disease-specific markers have improved.Improvement from baseline

      Laboratory values include ferritin, platelets, AST, triglycerides, and fibrinogen; disease-specific markers include fever, hepatosplenomegaly, lymphadenopathy, central nervous system dysfunction, hemorrhagic manifestations, complete blood count, fibrinogen/D-dimer, soluble CD25, or other cytokine markers.

    • Continued medical need: Documentation supports continued medical need for Gamifant.
    • Tolerability: There is no evidence of intolerable adverse effects or drug toxicity, including serious infections or severe infusion reactions.

    Covered indications

    Covered for the following FDA-approved indications:

    Covered indications: The patient is an adult or pediatric patient, including newborns and older, with either primary HLH with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy, or HLH/MAS in known or suspected Still's disease, including systemic juvenile idiopathic arthritis, with inadequate response or intolerance to glucocorticoids or recurrent MAS.

    Coverage is not supported when the member has an active or latent untreated infection, including a clinically important localized infection such as untreated hepatitis B or tuberculosis. The prescriber must attest to the member’s infection status in accordance with the FDA label.

    For primary HLH, Gamifant is supported only before hematopoietic stem cell transplantation (HSCT) for induction or maintenance. Use after the member has received HSCT, or continuation after HSCT conditioning begins, is not supported; treatment must be discontinued when conditioning for HSCT is initiated.

    Uses other than the covered FDA-approved indications are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    Do not administer Gamifant to members with untreated infections caused by mycobacteria, Herpes Zoster virus, or Histoplasma capsulatum.

    Do not administer live or live attenuated vaccines during Gamifant treatment or for at least 4 weeks after the last dose. The safety of live vaccination during or after emapalumab treatment has not been studied.

    Continuation of Gamifant is not medically necessary when the member no longer requires therapy for HLH/MAS. In that circumstance, Gamifant must be discontinued in accordance with the FDA label.

    Initial Authorization Criteria

    Primary HLH initial therapy

    Primary HLH initial therapy is authorized when all criteria are met.

    • Diagnostic confirmation

      • Genetic confirmation: Genetic testing shows a mutation known to cause HLH, such as PRF1, UNC13D, or STX11.
      • Clinical and laboratory findings: The member has five of the listed HLH findings.5 findings

        Findings include fever >38.5 C for >7 days; splenomegaly; cytopenias affecting 2 of 3 lineages; hypertriglyceridemia and/or hypofibrinogenemia; hemophagocytosis without malignancy; low or absent NK-cell activity; ferritin ≥500 mcg/L; or soluble CD25 >2400 U/mL.

    • Primary cause excluded:

    Continuation Authorization Criteria

    Primary HLH continuation

    Primary HLH continuation is authorized when all criteria are met.

    • Ongoing treatment need and no HSCT: The member has not received HSCT and continues to require therapy for HLH.
    • Clinical improvement: Disease-specific markers have improved, including applicable clinical, hematologic, ferritin, fibrinogen/D-dimer, lymphocyte, or cytokine markers.Improvement from baseline

      Additional markers that were especially high at diagnosis may also be used, such as NK-cell function or viral titers.

    • Tolerability: There is no evidence of intolerable adverse effects or drug toxicity, including serious infections or severe infusion reactions.

    Dosing and Quantity Limits

    Gamifant (emapalumab) dosing
    Starting dose1 mg/kg twice per week
    Maximum dose10 mg/kg per dose IV twice per week
    Quantity allowanceApproval quantity should account for titration needs; refer to dose titration in the product label
    Primary HLH dosing
    Starting dose1 mg/kg twice per week
    Maximum dose10 mg/kg per dose twice per week
    Titration quantityApproval quantity should account for titration needs; refer to dose titration in the product label

    Diagnostic and Billing Coding

    HCPCS CodeHCPCS
    J9210Injection, emapalumab-lzsg, 1mg
    Primary HLH diagnostic findings
    FeverTemperature >38.5 °C for >7 days
    CytopeniasCytopenias affecting 2 of 3 lineages: hemoglobin <9 g/dL, platelets <100 × 10⁹/L, or neutrophils <1 × 10⁹/L
    Additional findingsFasting triglycerides >3 mmol/L or ≥265 mg/dL; hypofibrinogenemia ≤1.5 g/L; ferritin ≥500 mcg/L; soluble CD25 >2400 U/mL; splenomegaly; hemophagocytosis; or low/absent NK-cell activity
    Diagnostic requirementFive qualifying findings are required when genetic confirmation is not provided
    Secondary HLH/MAS diagnostic findings
    Ferritin thresholdFerritin >684 ng/mL

    Authorization, Documentation, and Denial Conditions

    Documentation Required

    Qualified Specialist Prescriber

    Gamifant must be prescribed by, or in consultation with, a qualified specialist experienced in HLH management.

    • Board-certified geneticist
    • Pediatric metabolic specialist
    • Hematologist
    • Rheumatologist
    • Physician experienced in management of HLH
    Prior Authorization

    Medical Necessity Review Required

    Coverage is subject to prior authorization and case-by-case medical necessity review. Molina may request additional information, including when updated FDA labeling affects review.

    • Submit all required clinical information with the request.

    Administration Setting

    Billing Rule

    Use a non-hospital facility-based location

    Infused Gamifant is recommended for pharmacy or medical benefit coverage when administered in a non-hospital facility-based location.

    Policy Background

    Gamifant (emapalumab-lzsg) is reviewed for treatment of primary hemophagocytic lymphohistiocytosis (HLH) and secondary HLH/macrophage activation syndrome (MAS), including disease associated with Still’s disease or systemic juvenile idiopathic arthritis. Primary HLH is a rapidly progressive hyperinflammatory syndrome, while MAS is a potentially life-threatening hyperinflammatory complication of systemic inflammatory disorders. Coverage review focuses on objective evidence of disease activity; continuation requires documented improvement in disease-specific clinical and laboratory markers. For primary HLH, the policy also addresses response to conventional HLH therapy, transplant eligibility, and use before HSCT.

    Clinical Definitions and Protocols

    Hemophagocytic lymphohistiocytosis (HLH)
    TermHemophagocytic lymphohistiocytosis (HLH)
    Disease typeA hyperinflammatory disorder
    Clinical contextHLH may present with unexplained cytopenias, hepatitis, inflammatory central nervous system findings, fever, or hepatosplenomegaly
    Macrophage activation syndrome (MAS)
    TermMacrophage activation syndrome (MAS)
    Clinical significanceA potentially life-threatening complication of systemic inflammatory disorders
    Common associations
    Policy Summary
    PayerMolina Healthcare
    PolicyGamifant (emapalumab-lzsg) Coverage Policy
    Policy CodePolicy C15970-A
    Change TypeNon-material revision
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionBefore initiating Gamifant, document testing for latent tuberculosis infection and evaluate tuberculosis risk factors.
    SourceLink
    On This Page
    Covered Indications and General Coverage RulesInitial Authorization CriteriaContinuation Authorization CriteriaDosing and Quantity LimitsDiagnostic and Billing CodingAuthorization, Documentation, and Denial ConditionsAdministration SettingPolicy BackgroundClinical Definitions and Protocols
    Baseline markers:
    Baseline disease-specific markers are documented, including applicable clinical findings, complete blood count, fibrinogen and/or D-dimer, soluble CD25, or other cytokine markers.

    Markers may include fever, hepatosplenomegaly, generalized lymphadenopathy, central nervous system dysfunction, and hemorrhagic manifestations.

  1. Glucocorticoid history: The member has an inadequate response, serious side effects, or a clinical contraindication to glucocorticoids.
  2. Infection status: The prescriber attests that the member does not have an active or latent untreated infection, including clinically important localized infection, according to the FDA label.

    Examples include hepatitis B and tuberculosis.

  3. Updated transplant plan: The updated treatment plan addresses anticipated HSCT or explains why HSCT is not appropriate at this time.
  4. Infection monitoring: The prescriber attests to ongoing monitoring for infection development according to the FDA label.

    Includes monitoring for tuberculosis and hepatitis B reactivation.

  5. Infection monitoring: The prescriber attests to ongoing monitoring for infection development according to the FDA label.

    Includes monitoring for tuberculosis and hepatitis B reactivation.

    The prescriber attests that malignancy, viral infection, and rheumatic disorders have been ruled out as potential primary causes of HLH.
  6. Active disease: The prescriber attests to currently active disease within the last 3 months.Within 3 months
  7. Refractory, recurrent, progressive, or intolerant disease: The member has not responded to or maintained a satisfactory response to conventional HLH therapy, or has serious side effects from conventional HLH treatment.

    Examples include dexamethasone, etoposide, cyclosporine A, and anti-thymocyte globulin.

  8. Transplant eligibility: The member is eligible for stem cell transplant and has not received HSCT.No prior HSCT
  9. Pre-HSCT use: Gamifant is used before HSCT for induction or maintenance and will be discontinued when conditioning begins.Before HSCT
  10. Baseline markers: Baseline disease-specific markers are documented, including applicable clinical findings, complete blood count, fibrinogen and/or D-dimer, ferritin, soluble CD25, or other cytokine markers.

    Markers may include fever, splenomegaly, and central nervous system symptoms.

  11. Concomitant dexamethasone: The treatment plan administers Gamifant concomitantly with dexamethasone.

    Claims may be reviewed for concomitant dexamethasone use.

  12. Infection status: The prescriber attests that the member does not have an active or latent untreated infection, including clinically important localized infection, according to the FDA label.

    Examples include hepatitis B and tuberculosis.

  13. Secondary HLH/MAS initial therapy

    Secondary HLH/MAS initial therapy is authorized when all criteria are met.

    • Underlying Still's disease: The member has confirmed or suspected Still's disease, including systemic juvenile idiopathic arthritis.
    • HLH/MAS diagnosis: The member has a documented diagnosis of HLH/MAS.
    • Diagnostic laboratory findings: Ferritin is >684 ng/mL and two qualifying laboratory findings are documented.Ferritin >684 ng/mL plus 2 findings

      Qualifying findings are platelets ≤181×10^9/L, AST >48 U/L, triglycerides >156 mg/dL, or fibrinogen ≤360 mg/dL.

    • Baseline markers: Baseline disease-specific markers are documented, including applicable clinical findings, complete blood count, fibrinogen and/or D-dimer, soluble CD25, or other cytokine markers.

      Markers may include fever, hepatosplenomegaly, generalized lymphadenopathy, central nervous system dysfunction, and hemorrhagic manifestations.

    • Glucocorticoid history: The member has an inadequate response, serious side effects, or a clinical contraindication to glucocorticoids.
    • Infection status: The prescriber attests that the member does not have an active or latent untreated infection, including clinically important localized infection, according to the FDA label.

      Examples include hepatitis B and tuberculosis.

  14. Updated transplant plan: The updated treatment plan addresses anticipated HSCT or explains why HSCT is not appropriate at this time.
  15. Infection monitoring: The prescriber attests to ongoing monitoring for infection development according to the FDA label.

    Includes monitoring for tuberculosis and hepatitis B reactivation.

  16. Secondary HLH/MAS continuation

    Secondary HLH/MAS continuation is authorized when all criteria are met.

    • Clinical and laboratory improvement: Laboratory values and disease-specific markers have improved.Improvement from baseline

      Laboratory values include ferritin, platelets, AST, triglycerides, and fibrinogen; disease-specific markers include fever, hepatosplenomegaly, lymphadenopathy, central nervous system dysfunction, hemorrhagic manifestations, complete blood count, fibrinogen/D-dimer, soluble CD25, or other cytokine markers.

    • Continued medical need: Documentation supports continued medical need for Gamifant.
    • Tolerability: There is no evidence of intolerable adverse effects or drug toxicity, including serious infections or severe infusion reactions.
    • Infection monitoring: The prescriber attests to ongoing monitoring for infection development according to the FDA label.

      Includes monitoring for tuberculosis and hepatitis B reactivation.

    Secondary HLH/MAS dosing
    Day 16 mg/kg
    Days 4–163 mg/kg every 3 days for 5 doses
    Day 19 and onward3 mg/kg twice per week
    Maximum dose10 mg/kg twice per week
    Cumulative dose limitMaximum cumulative dose of 10 mg/kg over 3 days; dosing frequency may increase to every 2 days or once daily
    Quantity allowanceApproval quantity should account for titration needs; refer to dose titration in the product label
    Required qualifying findingsAt least 2 additional laboratory findings are required
    Qualifying laboratory findingsPlatelets ≤181 × 10⁹/L, AST >48 U/L, triglycerides >156 mg/dL, or fibrinogen ≤360 mg/dL
    Primary HLH diagnostic criteria
    Required numberFive of eight criteria
    Clinical criteriaFever and splenomegaly
    Hematologic and inflammatory criteriaCytopenias affecting 2 of 3 lineages; hypertriglyceridemia and/or hypofibrinogenemia; hemophagocytosis; ferritin ≥500 mcg/L; or soluble CD25 ≥2400 U/mL
    Cellular immune criterionLow or absent natural killer-cell activity
    Cytopenia thresholds
    Hemoglobin<9 g/dL
    Platelets<100 × 10⁹/L
    Neutrophils<1 × 10⁹/L
    Lineage requirementCytopenias affecting 2 of 3 peripheral blood lineages
    Hypertriglyceridemia or hypofibrinogenemia thresholds
    Fasting triglycerides>3 mmol/L or ≥265 mg/dL
    Fibrinogen≤1.5 g/L
    Diagnostic relationshipHypertriglyceridemia and/or hypofibrinogenemia satisfies this criterion
  17. Coverage may be determined case by case until Molina updates its criteria.
  18. Documentation Required

    General Documentation Required

    Molina may request additional documentation for coverage determination, quality improvement, and fraud, waste, and abuse prevention. Records may include patient records, test results, and credentials of the provider ordering or performing the drug or service.

    • Provide medical records, test results, provider credentials, and medical rationale when requested.
    • Molina may deny reimbursement or take other appropriate action when documentation does not support medical necessity, non-investigational use, benefit coverage, or appropriate billing practices.
    Documentation Required

    Diagnosis Documentation

    Document the applicable diagnosis of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS).

    • Primary HLH
    • Secondary HLH/MAS, including Still’s disease or systemic juvenile idiopathic arthritis when applicable
    Documentation Required

    Submit Weight or Dosing Data

    When dosing is based on weight, body surface area, or another member-specific measurement, submit the applicable dosing data as part of the medical necessity review.

    • Include current member-specific measurement(s) used to calculate the requested dose.
    Documentation Required

    Specialist Consultation Documentation

    If the prescriber does not meet the listed specialist qualifications, submit consultation documentation with both the initial request and each reauthorization request.

    • Consultation notes must identify the qualified consulting specialist and address the member’s HLH/MAS management.
    Documentation Required

    Clinical Medical Records

    Submit indication-specific clinical records supporting the diagnosis, disease activity, required laboratory or diagnostic findings, treatment history, and response or intolerance to prior therapy.

    • Primary HLH: genetic testing or qualifying clinical criteria; exclusion of malignancy, viral infection, and rheumatic disorders; active disease; refractory, recurrent, or progressive disease or serious toxicity with conventional HLH therapy; transplant eligibility and no prior HSCT.
    • Primary HLH: baseline disease markers such as fever, splenomegaly, CNS symptoms, CBC, fibrinogen and/or D-dimer, ferritin, soluble CD25, and other relevant cytokine markers; document concomitant dexamethasone treatment.
    • Secondary HLH/MAS: Still’s disease or sJIA, documented HLH/MAS, ferritin >684 ng/mL plus at least two qualifying findings, baseline disease-specific markers, and inadequate response, serious side effects, or contraindication to glucocorticoids.
    • Document the required infection attestation and applicable treatment plan.
    Documentation Required

    Evaluate for Latent Tuberculosis

    Before initiating Gamifant, test for latent tuberculosis using a purified protein derivative (PPD) or an IFN-γ release assay and evaluate the member’s tuberculosis risk factors.

    • Document the tuberculosis test and risk evaluation before treatment begins.
    Documentation Required

    Tuberculosis Prophylaxis

    Document tuberculosis prophylaxis for members at risk for tuberculosis or with a positive PPD or IFN-γ release assay.

    • Provide prophylaxis documentation before or in connection with Gamifant initiation, as clinically appropriate.
    Documentation Required

    Consider Infection Prophylaxis

    Consider prophylactic treatment against Herpes Zoster, Pneumocystis jirovecii, and fungal infections before or during Gamifant treatment, as clinically appropriate.

    • Document the prophylaxis plan or clinical rationale when prophylaxis is considered.
    Documentation Required

    Tuberculosis Screening and Prophylaxis

    Complete tuberculosis screening and risk evaluation before Gamifant initiation, and provide prophylaxis when the member is at risk or has a positive tuberculosis test.

    • Use a PPD or IFN-γ release assay for latent tuberculosis testing.
    • Evaluate tuberculosis risk factors before treatment.
    Denial Risk

    Insufficient or Inappropriate Documentation

    Molina may deny reimbursement or take additional appropriate action when submitted documentation is insufficient, does not support medical necessity or covered non-investigational use, or indicates inappropriate or excessive billing or other practices.

    • Respond to requests for additional records, test results, credentials, or medical rationale.
    • Ensure documentation supports the initial coverage determination and the member’s benefit coverage.
    Denial Risk

    Clinical Criteria Not Met

    Coverage may be denied when the applicable clinical criteria are not documented or are not met, including the required diagnosis or disease confirmation, active disease, qualifying treatment history or response, baseline markers, concomitant therapy, transplant status, or infection status.

    • Primary HLH: criteria include qualifying genetic or clinical confirmation, exclusion of alternative causes, active disease, refractory/recurrent/progressive disease or serious toxicity with conventional therapy, transplant eligibility without prior HSCT, and use before HSCT.
    • Secondary HLH/MAS: criteria include Still’s disease or sJIA when applicable, documented HLH/MAS, required ferritin and laboratory findings, baseline markers, and inadequate response, serious side effects, or contraindication to glucocorticoids.
    • Do not administer when the member has an active or latent untreated infection, including clinically important localized infections, as described in the FDA label.
    Denial Risk

    Continuation Criteria Not Met

    Reauthorization may be denied when the member no longer demonstrates improvement or ongoing medical need, develops intolerable adverse effects or toxicity, lacks an updated treatment plan, or required infection monitoring is not documented.

    • Primary HLH: document no prior HSCT, continued need, improvement in disease-specific markers, tolerability, and an updated HSCT or non-HSCT rationale.
    • Secondary HLH/MAS: document improvement in laboratory values and disease-specific markers and continued medical need.
    • Document ongoing monitoring for infection, including tuberculosis and Hepatitis B reactivation; discontinue when the member no longer requires HLH/MAS therapy.
    Denial Risk

    Unqualified Prescriber or Missing Consultation Notes

    Requests may be denied when the prescriber does not meet the specialist requirements or when required consultation notes are missing from the initial request or reauthorization request.

    • Use a qualified specialist prescriber or submit the required specialist consultation documentation.
    Denial Risk

    Infection or Transplant-Related Safety Issue

    Monitor for infection throughout treatment, including tuberculosis and Hepatitis B reactivation, according to the FDA label. For primary HLH, discontinue Gamifant when initiating conditioning for stem cell transplant.

    • Document ongoing infection monitoring for continuation requests.
    • Gamifant is used before HSCT for induction or maintenance and must be discontinued when conditioning begins.
    • Discontinue when the member no longer requires treatment for HLH/MAS.
    Denial Risk

    Unapproved or Investigational Use

    All uses other than the covered indications are considered experimental or investigational and follow Molina’s Off-Label policy.

    • Submit off-label requests under the applicable Molina Off-Label policy.
    Denial Risk

    Untreated Infection

    Do not administer Gamifant to patients with untreated infections caused by mycobacteria, Herpes Zoster virus, or Histoplasma capsulatum.

    • Evaluate and address specified untreated infections before administration.
    Denial Risk

    Live Vaccine Restriction

    Do not administer live or live attenuated vaccines during Gamifant treatment or for at least 4 weeks after the last dose.

    • The safety of live vaccination during or after emapalumab treatment has not been studied.
    Occurs most commonly in systemic juvenile idiopathic arthritis and adult-onset Still's disease
    Inflammatory mechanismAn uncontrolled immune response involving continual activation and expansion of T lymphocytes and macrophages, with massive cytokine secretion
    Secondary HLH/MAS
    TermSecondary HLH/MAS
    Underlying disease associationConfirmed or suspected Still's disease
    Included conditionSystemic juvenile idiopathic arthritis (sJIA)
    Policy diagnosisA documented diagnosis of hemophagocytic lymphohistiocytosis/macrophage activation syndrome is required
    Primary hemophagocytic lymphohistiocytosis (HLH)
    TermPrimary hemophagocytic lymphohistiocytosis (HLH)
    Disease courseA rapidly progressive syndrome
    Typical populationPrimarily affects children
    Underlying mechanismMassive hyperproduction of interferon gamma
    Macrophage activation syndrome (MAS)
    TermMacrophage activation syndrome (MAS)
    SeverityPotentially life-threatening
    Disease settingA complication of systemic inflammatory disorders, most commonly systemic juvenile idiopathic arthritis and adult-onset Still's disease
    Characteristic featuresHigh, nonremitting fever, hepatosplenomegaly, generalized lymphadenopathy, central nervous system dysfunction, and hemorrhagic manifestations
    HLH-94 protocol
    Protocol componentsWeekly dexamethasone and etoposide (VP-16)
    Central nervous system treatmentIntrathecal methotrexate and hydrocortisone are given for central nervous system disease
    Post-induction approachPatients who are recovering are weaned off therapy; patients who are not improving continue therapy as a bridge to allogeneic hematopoietic cell transplantation
    Transplant contextHematopoietic cell transplantation is required for patients with an HLH gene mutation, central nervous system disease, or disease relapse